Evidence Based Medicine for Diabetes Past, Present, and Future: Individualizing Diabetes Treatments. Ken Kortas, PharmD
|
|
- Sharyl Dalton
- 7 years ago
- Views:
Transcription
1 Evidence Based Medicine for Diabetes Past, Present, and Future: Individualizing Diabetes Treatments Ken Kortas, PharmD
2 Evidence Based Medicine for Diabetes: Past, Present and Future Individualizing Diabetes Treatments Ken Kortas BS Pharm, PharmD Senior Regional Medical Liaison Diabetes Field Medical Team US Medical Affairs Sanofi U.S. ADA Northern Illinois Chapter
3 Disclaimer Senior Regional Medical Liaison Diabetes Field Medical Team US Medical Affairs Sanofi U.S.
4 Objectives Discuss the epidemic of diabetes and the clinical impact Discuss the association between diabetes, hyperglycemia and complications Discuss the Evidence Based Medicine for reducing the risk of diabetes complications Discuss various management strategies for diabetes
5 The Diabetes Epidemic and the Clinical Impact
6 Natl Hx DM2 & Incretin Effect
7 Natural History of Type 2 Diabetes A Progressive Disease Obesity IFG * Diabetes Uncontrolled Hyperglycemia Glucose (mg/dl) Relative Function (%) *IFG=Impaired Fasting Glucose Post-meal Glucose β-cell Failure Years Of Diabetes Fasting Glucose Insulin Resistance Insulin Level Adapted with permission from Bergenstal R et al. Endocrinology. W.B. Saunders Company; 2001:
8 Diagnosis of Diabetes and Categories of Increased Risk for Diabetes Test Categories of Increased Risk Pre-Diabetes Diabetes FPG IFG: FPG mg/dl FPG 126 mg/dl 2-h PG on the 75-g OGTT IGT: 2-h PG mg/dl 2-h PG 200 mg A1C 5.7%-6.4% 6.5% In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random PG 200 mg/dl is also a criterion for the diagnosis of diabetes. FPG = fasting plasma glucose; IFG = impaired fasting glucose; IGT = impaired glucose tolerance; OGTT = oral glucose tolerance test; PG = plasma glucose. ADA. Diabetes Care. 2010;33(suppl 1):S11-S61.
9 Overview of the Diabetes Epidemic in the United States 25.8 million people or 8.2% of the population have diabetes 7.0 million are undiagnosed CDC projection that one-third of all U.S. adults will have diabetes by : For people aged 20 years, 1.9 million were newly diagnosed with diabetes & 26.9% of adults 65 years (10.9 million) had diabetes Increasing incidence of T2DM in children and adolescents Increasing incidence related to obesity, age, physical activity, and growth of ethnic populations 79 million Americans (46 million in 2007) with prediabetes: 33% US adults >20 yoa Gestational and Drug-Induced diabetes The total estimated cost of diabetes in 2007 was $174 billion, including $116 billion in excess medical expenditures CDC. National Diabetes Fact Sheet, 2007, US Dept of Health and Human Services. Accessed February, 20, ADA June 2008, Diabetes Forecast Oct-Nov
10 The Diabetes Epidemic CDC
11 The Cost of Diabetes (105 Million Americans with Diabetes or Pre-Diabetes) The estimated annual cost of diabetes in the US in 2012 is 245 Billion dollars Every 24 hours in the US 132 people start dialysis 2º to DM (2008) 166 people have lower-limb(s) amputated (2006) 66 people lose their eyesight (2007) % of all DM patients die from CV events Average medical expenses are more than twice as high for a person with diabetes s they are for a person without diabetes The risk of death with diabetes is TWICE that of similar age people without diabetes Death rates for women aged years with diabetes are more than 3 times the rate for women without diabetes ADA. Diabetes Care April 2013;36(4):
12 Clinical Impact of Diabetes Seventh leading cause of death (likely to be underreported)-overall, the risk of death among people with diabetes is twice that of non-diabetics Major cause of premature death and disability in the United States 67% of adults with diabetes have blood pressure greater than 130/80 or use hypertensive medications Leading cause of new cases of blindness in working-aged adults (24,000 new cases each year: 66 cases per day) National Diabetes Fact Sheet, Dept. of Health and Human Services, CDC,
13 Clinical Impact of Diabetes (cont.) More than 60% of nontraumatic lower extremity amputations (82,000 amputations in 2002: 225 per day, 166 per day 2006) About 60-70% of patients with diabetes have some form of mild to severe nervous system damage 44% of new cases of end-stage renal disease (in ,215 patients with diabetes began ESRD treatment: 132 per day) 2 to 4 fold increase in cardiovascular risk and stroke: over 2/3 of people with diabetes die from heart disease National Diabetes Fact Sheet, Dept. of Health and Human Services, CDC, 2005,
14 IDF. Diabetes Atlas, 5th Ed The Diabetes Epidemic: Global Projections,
15 Diabetes, Hyperglycemia and Complications
16 Main Pathophysiological Defects in T2DM incretin effect gut carbohydrate delivery & absorption pancreatic glucagon secretion pancreatic insulin secretion HYPERGLYCEMIA? + hepatic glucose production peripheral glucose uptake Adapted from: Inzucchi SE, Sherwin RS in: Cecil Medicine 2011
17 Complications of Type 2 Diabetes Heart Coronary heart disease Cardiovascular disease Blood Vessels Peripheral artery disease Intermittent claudication Kidneys Microalbinuria Nephropathy Hyperglycemia Eyes Retinopathy Glaucoma Nerves Neuropathy Gastroparesis Source: American Diabetes Association. Diabetes Care 2006;29(Suppl 1):S4-S42.
18 Diabetes: Magnitude of Complications Leading cause of blindness in working age adults Diabetic Retinopathy Stroke 2- to 4-fold increase in cardiovascular mortality and stroke CVD Diabetic Nephropathy Leading cause of end-stage renal disease Diabetic Neuropathy Leading cause of nontraumatic lower extremity amputations CVD = cardiovascular disease. National Diabetes Information Clearinghouse. At: Responsible for 66% of diabetesrelated mortality
19 Various Mechanisms Link Hyperglycemia and Atherothrombosis Hyperglycemia Inflammation Oxidative Stress Endothelial Dysfunction Thrombosis MMP-9 MMP-2 NF-κB ROS Generation O 2 (superoxide) enos Egr-1 Inflammatory activity TNF-α, IL-6 MCP-1 sicam-1 Lipid peroxidation Protein carbonylation DNA damage NO +O 2 ONO O 2 NO Vasoconstriction Cytotoxicity PAI-1 TF Thrombosis Fibrinolysis Atherothrombosis Beckman JA et al. JAMA. 2002;287: ; Garg R et al. Stroke. 2006;37:
20 Estimated Average Glucose (eag) and A1c (Normal 4-5.6%) A1c (%) eag mg/dl (95% CI)* 5 97 (76-120) ( ) ( ) ( ) ( ) ( ) ( ) ( ) Data in parentheses are 95% CIs. *Linear regression eag (mg/dl) = 28.7 x A1c Nathan, et.al. DIABETES CARE, AUGUST 2008
21 Guidelines for Glycemic, BP, & Lipid Control HbA1C Preprandial glucose Postprandial glucose American Diabetes Assoc. Goals < 7.0% (individualization) mg/dl ( mmol/l) < 180 mg/dl Blood pressure < 130/80 mmhg Lipids HDL = high-density lipoprotein; LDL = low-density lipoprotein; PG = plasma glucose; TG = triglycerides. LDL: < 100 mg/dl(2.59 mmol/l) < 70 mg/dl(1.81 mmol/l)(with overt CVD) HDL: > 40 mg/dl(1.04 mmol/l) > 50 mg/dl(1.30 mmol/l) TG: < 150 mg/dl(1.69 mmol/l) ADA. Diabetes Care. 2012;35:S11-63
22 Evidence Based Medicine Trials for Diabetes
23 Good Glycemic Control May Help Reduce Incidence of Complications DCCT Kumamoto UKPDS Complication A1C: 9%-7% A1C: 9%-7% A1C: 8%-7% % reduction Retinopathy Nephropathy Neuropathy 60 Macrovascular disease 41* 16 ** * Not statistically significant. **Myocardial infarction (P=0.052)-not statistically significant DCCT = Diabetes Control and Complications Trial; UKPDS = United Kingdom Prospective Diabetes Study. DCCT Research Group. N Engl J Med. 1993;329: Ohkubo et al. Diabetes Res Clin Pract. 1995;28: UKPDS 33. Lancet. 1998;352:
24 UK Progressive Diabetes Study (UKPDS) Newly diagnosed T2DM patients in 2 study arms UKPDS 33 Conventional treatment (diet) vs. Sulfonylurea or Insulin (n=3867, median age 54 years) 10 years of follow-up median (p<0.0001) C: A1c 7.9% I: A1c 7.0% incidence of weight gain and hypoglycemia in the intensive treatment group (P<0.001) 12% any diabetes-related endpoint (P=0.029) 25% microvascular endpoint (P=0.0099) UKPDS 33. Lancet 1998;352:
25 UK Progressive Diabetes Study (UKPDS) Newly diagnosed T2DM patients in 2 study arms UKPDS 34 Conventional treatment (diet) vs. Metformin (n=753, mean age 53 years) All patients overweight (>120% IBW) 10 year follow-up median C: A1c 8.0% vs. I: A1c 7.4% 32% any diabetes-related endpoint (P=0.0023) 42% any diabetes-related death (P=0.017) 36% all-cause mortality (P=0.011) UKPDS 33. Lancet 1998;352: UKPDS 34. Lancet 1998;352:
26 Results from the UKPDS: Correlation Between a 1.0% A1C Decrease and Reduced Risk of Complications P< for microvascular complications, diabetes-related death, myocardial infarction, and all-cause mortality. UKPDS = UK Prospective Diabetes Study. Stratton IM et al. BMJ. 2000;321(7258):
27 Glycemic Control Reduces Risk of Type 2 Diabetes Complications Risk reduction with 1% decline in updated A1c P< P=0.035 P=0.021 P< MI Stroke Heart failure Cataract extraction Microvascular disease PVD Source: Stratton IM, et.al (UKPDS). BMJ2000;321:
28 UK Progressive Diabetes Study (UKPDS) Newly diagnosed T2DM patients in 2 study arms UKPDS 34 Conventional treatment (diet) vs. Metformin (n=753, mean age 53 years) All patients overweight (>120% IBW) 10 year follow-up median C: A1c 8.0% vs. I: A1c 7.4% 32% any diabetes-related endpoint (P=0.0023) 42% any diabetes-related death (P=0.017) 36% all-cause mortality (P=0.011) Greater any diabetes-related endpoint, all-cause mortality or stroke with metformin vs. sulfonylurea/insulin group (P<0.03) UKPDS 33. Lancet 1998;352: UKPDS 34. Lancet 1998;352:
29 UKPDS 10 year follow-up Post UKPDS trial monitoring Does improved glucose control persist? What are the long-term effects on macrovascular outcomes? Results 3277 of the original 9311 patients Between group differences in A1c lost 1 year post UKPDS conclusion Holman RR, et al. N Engl J Med 2008;359:
30 UKPDS 10 year follow-up Sulfonylurea/Insulin vs. Conventional: 9% any diabetes-related endpoint (P=0.04) 24% microvascular disease (P=0.001) 17% diabetes-related death (P=0.01) 15% myocardial infarction (P=0.01) 13% death from any cause (P=0.007) Metformin vs. Conventional: 21% any diabetes-related endpoint (P=0.01) 33% myocardial infarction (P=0.005) 30% diabetes-related death (P=0.01) 27% death from any cause (P=0.002) Legacy Effect Holman RR, et al. N Engl J Med 2008;359:
31 UKPDS: Benefit of Intensified Treatment in Newly Diagnosed Type 2 Diabetes (Legacy Effect of Earlier Glucose Control) Median of 8.5 years post-trial follow-up of UKPDS sulfonylurea-insulin group Aggregate endpoint 1997* 2007 Any diabetes related endpoint RRR p 12% % 0.04 Microvascular disease RRR p 25% % Myocardial infarction RRR p 16% % 0.01 All-cause mortality RRR p 6% % Holman RR, et al. N Engl J Med 2008;359: UKPDS Group. Lancet 1998;352: *End of randomized intervention. p=log rank. RRR, relative risk reduction.
32 UKPDS: Post-Trial Monitoring Any Diabetes-related Endpoint To determine the longer-term impact of earlier improved glucose control on microvascular and on macrovascular outcomes Intervention Trial Median follow-up 10.0 years Intervention Trial + Post-trial monitoring Median follow-up 16.8 years RR=0.88 ( ) P=0.029 Conventional Conventional Sulfonylurea/ Insulin Sulfonylurea/ Insulin Holman et al. N Eng J Med 2008;
33 Diabetes Control and Complications Trial (DCCT) 1441 patient with T1DM average follow-up 6.5 years Intensive vs. conventional treatment Conventional arm: 1-2 daily insulin injections Intensive arm: 3 daily insulin injections or use of an insulin pump Goal to minimize symptomatic hyper or hypoglycemia Goal preprandial glucose mg/dl, postprandial <180 mg/dl, weekly 3 am >65 mg/dl and A1c <6.05% At study conclusion the A1c in the intensive treatment group was 7.4% versus 9.1% in the conventional treatment group DCCT. N Engl J Med 1993;329:
34 Good Glycemic Control May Help Reduce Incidence of Complications DCCT Kumamoto UKPDS Complication A1C: 9%-7% A1C: 9%-7% A1C: 8%-7% % reduction Retinopathy Nephropathy Neuropathy 60 Macrovascular disease 41* 16 ** * Not statistically significant. **Myocardial infarction (P=0.052)-not statistically significant DCCT = Diabetes Control and Complications Trial; UKPDS = United Kingdom Prospective Diabetes Study. DCCT Research Group. N Engl J Med. 1993;329: Ohkubo et al. Diabetes Res Clin Pract. 1995;28: UKPDS 33. Lancet. 1998;352:
35 Epidemiology of Diabetes Interventions and Complications (EDIC) Primary goal to determine the long-lasting effects of intensive vs. conventional glycemic control on cardiovascular disease incidence Approximately 17 years of follow-up of 93% of DCCT participants All patients offered intensive treatment Diabetes management returned to PCP A1C differences diminished quickly Average in each group was approximately 8% NEJM 2005:353(25):
36 DCCT EDIC: Intensive Diabetes Therapy Reduced Risk of CVD Events in Type 1 Diabetes Cumulative Incidence Any Predefined CVD Outcome 42% Risk Reduction (95% CI, 9%-63%; P = 0.02) Conventional Treatment Intensive Treatment Nonfatal MI, Stroke, or Death From CVD 57% Risk Reduction (95% CI, 12%-79%; P = 0.02) Years Since Entry Predefined CVD outcome = nonfatal MI or stroke; death judged to be due to CVD; subclinical MI; angina, confirmed by ischemic changes on exercise tolerance testing or by clinically significant obstruction on coronary angiography; or the need for revascularization with angioplasty or coronary artery bypass. Nathan DM et al for the DCCT/EDIC Study Research Group. N Engl J Med. 2005;353: Years Since Entry 36
37 ADA Scientific Conference: 30th Anniversary Symposium for DCCT/EDIC One of the most exciting presentations was the 30th Anniversary Symposium for DCCT/EDIC, the largest long-term study of people with diabetes. The program has continued to find that early efforts at intensive blood sugar management continue to lower the long-term risk of complications decades later. They reported that those interventions have reduced the risk of eye disease by 50%, heart disease and stroke by 60% and kidney disease by 61%. Even a five-year period of better A1cs means lower complications decades later. 37
38 DCCT/EDIC 30 Years Later: Positive Effects of Intensive Therapy Confirmed in Type 1 Diabetes We are very excited by the long-term results of these studies, David M. Nathan, MD, director of the Massachusetts General Hospital Diabetes Center and co-chair of the studies, What we knew about intensive insulin therapy before 1993 was that it caused hypoglycemia that we were concerned about. What surprised us most by the DCCT results in 1993 was that the magnitude of the effects was far greater than anyone ever anticipated. However, the demonstrated effects were on the early stages of complications (microvascular: retinopathy, neuropathay and nephropathy). 38
39 DCCT/EDIC 30 Years Later: Positive Effects of Intensive Therapy Confirmed in Type 1 Diabetes-Dr. Lachin We now have compelling data that intensive therapy prevents or delays the advanced stages of diabetes complications In particular, Dr. Lachin focused on results published in the New England Journal of Medicine in These data linked intensive therapy with about a 57% reduction in the risk for major CVD events during the first 11 years of EDIC combined with the 10 years of DCCT. It turns out that those treatment effects were almost all explained by differences in level of HbA1c in the former intensive treatment group during the DCCT. Metabolic or glucose memory John Lachin, ScD, the principal investigator of the DCCT/EDIC Coordinating Center at The George Washington University in Washington, D.C., ADA 73 rd Scientific Session, Chicago June 22,
40 DCCT/EDIC 30 Years Later: Positive Effects of Intensive Therapy Confirmed in Type 1 Diabetes-Dr. Lachin Another important outcome is mortality: In terms of diabetic eye disease, there was a 50% reduction in the severe stages of diabetic eye disease as well as the need for ocular surgery and procedures in the original intensive therapy group. Although we have means of treating severe eye disease to prevent vision loss, it is always better to reduce its development in the first place to avoid the need for expensive and only partly effective late-stage therapies, Intensive diabetes therapy effectively accomplishes this goal. 40
41 DCCT/EDIC 30 Years Later: Positive Effects of Intensive Therapy Confirmed in Type 1 Diabetes-Dr. Lachin Almost as impressive as the actual data is the length of follow-up. Ninety-five percent of the surviving patients who continue to participate after 30 years, which is unprecedented. The reason for this is that patients have benefited, This also demonstrates the importance of continued follow-up and long-term results from interventions in diabetes. Diabetes is a lifelong disease. By following these participants for 3 decades, instead of showing what a drug or therapy does over 6 months or 1 year, what matters to people is what s going to happen over the course of a life, both in terms of the effect of the therapy and also the course of type 1 diabetes in today s world with contemporary therapy. 41
42 DCCT/EDIC 30 Years: The Lesson Learned is to Start Intensive Diabetes Management as Soon and as Safely as Possible ADA 2013 June 22, 2013 In the Intensive-treatment group at year 14 of EDIC: Neuropathy findings: 30% reduction in development of confirmed neuropathy 31% reduction in confirmed autonomic neuropathy Microalbuminuria: at 18 years a 39% RR for development among patients who did not have at the start of DCCT., at 8 yrs-57% RR Retinopathy difference Intensive vs Conventional treatment 70% RR at 4 years, 53% at 10 years and 46% at 18 years At 9 years into EDIC, 42% decrease in any CVE and a 57% RR for nonfatal heart attack, stroke, or death from CVD (NEJM 2005)-extended thru 2012 RR of 33% and 35% Mortality in the EDIC-soon to be published, but stated no increased mortality among the intensive treated group (Dr Lachin ADA 2013) 42
43 Action to Control Cardiovascular Risk in Diabetes Trial (ACCORD) Whether tight glycemic control improves cardiovascular event rates in T2DM patients patients with an average age of 62 years and duration of diabetes of 10 years A1c target <6% vs % 35% positive history of CVD Glycemic control arm was terminated early Intensive arm: A1c 6.4% vs. Conventional arm: A1c 7.5% 3.5 year follow-up 22% death from any cause (P=0.04) Subgroup: Patients with shorter duration of diabetes, without positive CVD history and/or a baseline A1c <8% saw significant in nonfatal MI, nonfatal stroke, and death from cardiovascular causes Skyler JS, et al. Circulation. 2009;119:1-7 43
44 Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Effect of intensive glucose control on macrovascular and microvascular outcomes in T2DM patients patients with an average age of 66 years and duration of diabetes of 8 years 32% positive history of CVD A1c target 6.5% vs. local guidelines Achieved A1c 6.3% vs. 7.0% at 5 years of follow-up -10% in 1 outcome Combination of microvascular and major macrovascular events) Due to significant (14%) microvascular events No difference between groups for macrovascular event rate Skyler JS, et al. Circulation. 2009;119:
45 Veterans Affairs Diabetes Trial (VADT) Whether tight glycemic control improves cardiovascular event rates in T2DM patients 1791 patients with an average age of 60 years and duration of diabetes of 11.5 years 40% positive history of CVD A1c target 6% vs. planned separation of 1.5% Achieved A1c 6.9% vs. 8.5% at 5.6 years of follow-up No significant reduction in 1 end point MI, stroke, cardiovascular death, revascularization, heart failure hospitalizations, amputation Post hoc subgroup: Duration of DM < 12 years, lack of hypoglycemia in the previous 90 days and low baseline coronary artery calcium scores Intensive glycemic control significantly 1 end point Skyler JS, et al. Circulation. 2009;119:
46 Management Strategies 46
47 Normoglycemia and Recommended Glycemic Targets in T2DM Glucose Control Healthy 1 ADA 1 AACE 2 A1C, % <5.6 < Preprandial plasma glucose, mg/dl < <110 Peak postprandial glucose, mg/dl <140 <180 a <140 b a Peak postprandial capillary plasma glucose; b 2-hour postprandial glucose concentration; c Self-monitored blood glucose. ADA = American Diabetes Association; AACE = American Association of Clinical Endocrinologists; 1. ADA. Diabetes Care. 2009;32(suppl 1):S13-S61; 2. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. Endocr Pract. 2007;13(suppl 1):3-68;
48 What is the appropriate A1C target? What is the appropriate A1C target? Must individualize for each patient Challenges with Achieving A1c Goal: Late diagnosis and initiation of therapy Therapeutic inertia Lack of effective lifestyle intervention Secondary failure Adverse events associated with antihyperglycemic therapies Complexity of care Role of PPG in failure PPG = postprandial plasma glucose. Zambanini A et al. Diabetes Res Clin Pract. 1999;46: Clark M et al. Diabetic Med. 2003;20: Shah BR et al. Diabetes Care. 2005;28:
49 Figure 1 Diabetes Care, Diabetologia. 19 April 2012 [Epub ahead of print] (Adapted with permission from: Ismail-Beigi F, et al. Ann Intern Med 2011;154:554)
50 Goals of Diabetes Management Individualize treatment regimens Physiological treatment goals As near to normoglycemia (A1C < 7.0%) as possible while reducing the risk of significant hypoglycemia for non-pregnant adults Reduce the risk of short-term crises Hypoglycemia Hyperglycemia DKA Treat the whole patient Reduce the risk of long-term complications Benefits of BG, blood pressure, and lipid management are proven Treat diabetes comorbidity (hypertension, CVD, lipids, weight) BG = blood glucose; CVD = cardiovascular disease; DKA = diabetic ketoacidosis. ADA. Diabetes Care. 2010;33(suppl 1): 50
51 ADA-EASD Position Statement: Management of Hyperglycemia in T2DM 3. ANTI-HYPERGLYCEMIC THERAPY Glycemic targets - HbA1c < 7.0% (mean PG mg/dl [ mmol/l]) - Pre-prandial PG <130 mg/dl (7.2 mmol/l) - Post-prandial PG <180 mg/dl (10.0 mmol/l) - Individualization is key: Tighter targets ( %) - younger, healthier Looser targets ( %+ ) -older, comorbidities, hypoglycemia prone, etc. - Avoidance of hypoglycemia PG = plasma glucose Diabetes Care, Diabetologia. 19 April 2012 [Epub ahead of print]
52 Insulin Pathophysiologic Considerations BG Lowering Agents Insulin Insulin Insulin Kalusa, KM and Henry, RR, Expert Opin Pharmacother (2009) 10(5): (modified)
53 Lifestyle Intervention Medical nutrition therapy Weight loss for overweight or obese individuals Low-calorie diets Low-carbohydrate diets (monitor lipid profiles, renal function, and protein intake) Diets low in saturated fat Disease self-management education Should address psychological issues Skill-based approach: assist patients in making informed choices Individual- and group-based approaches Increase physical activity In appropriate individuals, at least 150 min/wk of moderate-intensity aerobic physical activity Higher levels of exercise intensity maybe associated with greater improvements in A1C ADA Clinical Practice Recommendations;
54 Numerous Pharmacologic Treatment Options Sulfonylureas: glipizide*, chlorpropamide, glyburide,* glimepiride, gliclazide Biguanides: metformin Thiazolidinediones (TZDs): rosiglitazone,* pioglitazone* α-glucosidase inhibitors: miglitol, acarbose Meglitinides: repaglinide, nateglinide Human insulin: regular human insulin (RHI), neutral protamine Hagedorn (NPH) Basal insulin analogs: insulins glargine and detemir Rapid-acting insulin analogs: insulins aspart, glulisine, and lispro Premix insulin: 70/30 NPH insulin/rhi; 50/50 NPH insulin/rhi; 70/30 NPA insulin/insulin aspart; 75/25 NPL insulin/insulin lispro Incretin mimetics (GLP-1): exenatide (Byetta and Bydueron ), liraglutide (Victoza ) Synthetic amylin: pramlintide DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin, dutogliptin Januvia (sitagliptin), Onglyza (saxagliptin) and Tradjenta (Linaglipitin) Bromocriptine-dopamine agonist: Cycloset Colesevelam-bile acid binder: Welchol *Also produced in combination with metformin; Not FDA approved. DPP-4 = dipeptidylpeptidase-4 enzyme; NPA = neutral protamine aspart; NPL = neutral protamine lispro. 54
55 Numerous Pharmacologic Treatment Options - Combination Pills Type 2 diabetes medications may be taken individually or in combination pills, such as those that combine glipizide with metformin (Metaglip), glyburide with metformin (Glucovance), sitagliptin with metformin (Janumet), linagliptin with metformin (Jentadueto), repaglinide with metformin (Prandimet), saxagliptin with extended-release metformin (Kombiglyze XR), and rosiglitazone with metformin (Avandamet) Combination pills offer convenience but can have the drawback of making it more difficult to determine which medication is causing a negative side effect. Diabetes Forecast, ADA,
56 ADA-EASD Position Statement: Management of Hyperglycemia in T2DM 3. ANTI-HYPERGLYCEMIC THERAPY Implementation strategies: - Initial therapy - Advancing to dual combination therapy - Advancing to triple combination therapy - Transitions to & titrations of insulin Diabetes Care, Diabetologia. 19 April 2012 [Epub ahead of print]
57 Diabetes Care, Diabetologia. 19 April 2012]
58 Approximating Nature With Insulin Therapy: The Basal/Prandial Concept Physiologic Insulin Secretion 24-Hour Profile Insulin (µu/ml) Glucose (mg/dl) Prandial Insulin 0 Basal Insulin Breakfast Lunch Supper Prandial Glucose AM PM Time of Day Basal Insulin Nearly constant levels Suppresses glucose production between meals and overnight 50% of daily needs Prandial Insulin Limits hyperglycemia after meals 10%-20% of total daily insulin per meal Basal Glucose Adapted with permission from Bergenstal RM et al. In: DeGroot LJ et al, eds. Endocrinology. 4th ed. WB Saunders Co.; 2001:821.
59 Cardiovascular Disease Coronary artery disease Avoid hypoglycemia Preferred drugs include: Metformin Pioglitazone, unless co-morbid heart failure Incretin-based therapies need long-term data Heart failure Avoid thiazolidinediones Metformin can be used if non-severe ventricular failure, stable cardiovascular status, and normal renal function Incretin-based therapies need long-term data Inzucchi SE, et al. Diabetes Care 2012;35:
60 Chronic Kidney Disease Increased risk for hypoglycemia Metformin should be avoided with more severe kidney disease US: if serum creatinine 1.5 mg/dl men and 1.4 mg/dl women UK: with GFR 30 ml/min and reduced dose at GFR of 45 ml/min Drugs not eliminated by kidneys (no restrictions) Pioglitazone Linagliptin Inzucchi SE, et al. Diabetes Care 2012;35:
61 Chronic Kidney Disease Caution with secretagogues (hypoglycemia risk) Glyburide should be specifically avoided Avoid exenatide if GFR < 30 ml/min All insulins are eliminated more slowly in patients with severe renal impairment Inzucchi SE, et al. Diabetes Care 2012;35:
62 Liver Disease Insulin is preferred in advanced disease Pioglitazone may benefit fatty liver disease Avoid if active liver disease or alanine transaminase > 2.5 times upper limit of normal Meglitinides can be used Avoid secretagogues in severe disease Avoid incretin-based drugs in comorbid pancreatitis Inzucchi SE, et al. Diabetes Care 2012;35:
63 Summary of ADA/EASD Position Statement Glycemic targets and glucose-lowering therapies must be individualized Diet, exercise, and education remain the foundation of any T2DM treatment program Unless there are prevalent contraindications, metformin is the optimal first-line drug After metformin, there are limited data to guide therapy Combination therapy with an additional 1 2 oral or injectable agents is reasonable, aiming to minimize side effects where possible Inzucchi SE, et al. Diabetes Care 2012;35:
64 Summary of 2012 ADA/EASD Position Statement Ultimately, many patients will require insulin therapy alone or in combination with other agents to maintain glucose control All treatment decisions, where possible, should be made in conjunction with the patient, focusing on his/her preferences, needs, and values Comprehensive cardiovascular risk reduction must be a major focus of therapy Inzucchi SE, et al. Diabetes Care 2012;35:
65 Diabetes Patients and Preventive Care : CDC 2012 We have work to do. Wisconsin Foot exams % eye exams % A1c 2x/yr-73.5% Daily SMBG- 60.1% Attended DM class -59.4% Annual Flu Vaccine- 62.4%
66 Impact of Diabetes-Take Home Message In the 60 minutes we ve spent here today talking about diabetes, the following has occurred: Leading cause of new cases of blindness in working-aged adults (24,000 new cases each year: 66 cases per day) 3 patients lost their eye site to diabetes More than 60% of non-traumatic lower extremity amputations (66,000 amputations in 2006: 180 per day) 8 patients had an amputation due to diabetes 44% of new cases of end-stage renal disease (in ,400 patients with diabetes began ESRD treatment: 122 per day) 5 patients started ESRD treatment due to diabetes National Diabetes Fact Sheet, Dept. of Health and Human Services, CDC,
67 Questions? Comments?
Diabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationMary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationVolume 01, No. 08 November 2013
State of New Jersey Department of Human Services Division of Medical Assistance & Health Services New Jersey Drug Utilization Review Board Volume 01, No. 08 November 2013 TO: SUBJECT: PURPOSE: Physicians,
More informationManaging Patients Newly Diagnosed with Diabetes. Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON
Managing Patients Newly Diagnosed with Diabetes Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON 1 Conflict Disclosure Information Conflict Disclosure Information
More informationDCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What
More informationUpdate on the management of Type 2 Diabetes
Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationStarting Insulin Sooner Than Later
Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration
More informationManagement of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationType 2 diabetes Definition
Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes
More informationHow To Treat Diabetes
Overview of Diabetes Medications Marie Frazzitta DNP, FNP c, CDE, MBA Senior Director of Disease Management North Shore LIJ Health Systems Normal Glucose Metabolism Insulin is produced by beta cells in
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationManagement of Type 2 Diabetes Mellitus in the Elderly
Management of Type 2 Diabetes Mellitus in the Elderly ANDREA FERENCZI, M.D. BANNER ARIZONA MEDICAL CLINIC DEPARTMENT OF ENDOCRINOLOGY Incidence and Prevalence of Diabetes in the United States County-level
More informationDefinition of Diabetes Mellitus
Definition of Diabetes Mellitus Diabetes mellitus consists of a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action or both. U.S. Diabetes
More informationDiabetes DIABETES MELLITUS. Types of Diabetes. Classification of Diabetes 6. 10. 2013. Prediabetes: IFG, IGT, Increased A1C
Diabetes Diabetes mellitus is a chronic disease characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. A state of raised blood glucose (hyperglycaemia)
More informationType 1 Diabetes ( Juvenile Diabetes)
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
More informationDistinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationGlucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationType 2 Diabetes in Children
Type 2 Diabetes in Children February 19, 2005 Brandon Nathan, MD Endocrinology Department of Pediatrics University of Minnesota Medical School University of Minnesota Masonic Children s Hospital Agenda
More informationPrimary Care Type 2 Diabetes Update
Primary Care Type 2 Diabetes Update May 16, 2014 Presented by: Barb Risnes APRN, BC-ADM, CDE Objectives: Discuss strategies to address common type 2 diabetes patient management challenges Review new pharmacological
More informationTrends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins
Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationManagement of Clients with Diabetes Mellitus
Management of Clients with Diabetes Mellitus Black, J.M. & Hawks, J.H. (2005) Chapters 47, (pp 1243-1288) 1288) Baptist Health School of Nursing NSG 4037: Adult Nursing III Carole Mackey, MNSc,, RN, PNP
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationTreating Type 2 Diabetes Mellitus: a New York State Medicaid Clinical Guidance Document
Treating Type 2 Diabetes Mellitus: a New York State Medicaid Clinical Guidance Document Disclaimer: This document is offered as a service to New York State Prescribers to inform about the most current
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines) Authors: Dr. M. Love, Kathy Harrigan Reviewers:
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationAdd: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above
Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationAntihyperglycemic Agents Comparison Chart
Parameter Metformin Sulfonylureas Meglitinides Glitazones (TZD s) Mechanism of Action Efficacy (A1c Reduction) Hepatic glucose output Peripheral glucose uptake by enhancing insulin action insulin secretion
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationSecond- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationDiabetes Fundamentals
Diabetes Fundamentals Prevalence of Diabetes in the U.S. Undiagnosed 10.7% of all people 20+ 23.1% of all people 60+ (12.2 million) Slide provided by Roche Diagnostics Sources: ADA, WHO statistics Prevalence
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated March 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationAcarbose INITIAL: 25 mg PO TID ($45) Miglitol INITIAL: 25 mg PO TID ($145)
PL Detail-Document #310601 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2015 Drugs for Type 2
More informationStrengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours
Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Presented by New York State Council of Health system Pharmacists October 18 19, 2013 St. John s University,
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationInsulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationDr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy
Dr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationNoninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause hypoglycemia MED GROUP DESCRIPTOR
Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause MED GROUP DESCRIPTOR INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) MICRONIZED GLYBURIDE*
More informationThe Challenge of Preventing and Treating Diabesity Los Angeles University of Best Practices
The Challenge of Preventing and Treating Diabesity Los Angeles University of Best Practices The Right Care Initiative Long Beach Memorial Hospital July 26, 2013 Francine Ratner Kaufman, MD Distinguished
More informationDM Management in Elderly- What are the glucose targets?
DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011 Disclosures
More informationDiabetes Medications. Minal Patel, PharmD, BCPS
Diabetes Medications Minal Patel, PharmD, BCPS Objectives Examine advantages and disadvantages of oral anti-hyperglycemic medications Describe the differences between different classes of insulin Explore
More informationPharmaceutical Management of Diabetes Mellitus
1 Pharmaceutical Management of Diabetes Mellitus Diabetes Mellitus (cont d) Signs and symptoms 2 Elevated fasting blood glucose (higher than 126 mg/dl) or a hemoglobin A1C (A1C) level greater than or equal
More informationMedicines for Type 2 Diabetes A Review of the Research for Adults
Medicines for Type 2 Diabetes A Review of the Research for Adults Is This Information Right for Me? Yes, if: Your doctor or health care provider has told you that you have type 2 diabetes and have high
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationTreatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.
National Diabetes Statistics What is diabetes? Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More information10/30/2012. Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University of South Alabama Mobile, Alabama
Faculty Medications for Diabetes Satellite Conference and Live Webcast Wednesday, November 7, 2012 2:00 4:00 p.m. Central Time Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University
More informationAdult Diabetes Clinician Guide
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction JANUARY 2016 This evidence-based guideline summary is based on the 2016 National Diabetes Guideline.
More informationBaskets of Care Diabetes Subcommittee
Baskets of Care Diabetes Subcommittee Disclaimer: This background information is not intended to be a comprehensive scientific discussion of the topic, but rather an attempt to provide a baseline level
More informationInsulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationFYI: (Acceptable range for blood glucose usually 70-110 mg/dl. know your institutions policy.)
How Insulin Works: Each type of insulin has an onset, a peak, and a duration time. Onset is the length of time before insulin reaches the bloodstream and begins lowering blood Peak is the time during which
More informationType 2 Diabetes. Jonathon M. Firnhaber, MD. Assistant Professor, Residency Program Director East Carolina University Greenville, North Carolina
Type 2 Diabetes Jonathon M. Firnhaber, MD Assistant Professor, Residency Program Director East Carolina University Greenville, North Carolina Verbal Disclosure It is the policy of the AAFP that all individuals
More informationCauses, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
More informationType 2 Diabetes Medicines: What You Need to Know
Type 2 Diabetes Medicines: What You Need to Know Managing diabetes is complex because many hormones and body processes are at work controlling blood sugar (glucose). Medicines for diabetes include oral
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationApproximate Cost Reference List i for Antihyperglycemic Agents
Alpha Glucosidase Inhibitor Acarbose (Glucobay ) Biguanides Metformin (Glucophage, generic) Metformin ER (Glumetza ) Approximate Cost Reference List i for Antihyperglycemic Agents Incretin Agents - DPP-4
More informationMedicines Used to Treat Type 2 Diabetes
Goodman Diabetes Service Medicines Used to Treat Type 2 Diabetes People who have type 2 diabetes may need to take medicine to help lower their blood glucose, in addition to being active & choosing healthy
More informationNutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
More informationPowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.
PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY 12a FOCUS ON Your Risk for Diabetes Your Risk for Diabetes! Since 1980,Diabetes has increased by 50 %. Diabetes has increased by 70 percent
More informationDIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS
Section Two DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS This section will: Describe oral agents (pills) are specific for treating type 2 diabetes. Describe other hypoglycemic agents used
More informationDisclosures. Types of Diabetes Mellitus. Type 1 Diabetes Mellitus. Principles of Basal-Bolus Insulin Therapy and Carbohydrate Counting
Principles of Basal-Bolus Insulin Therapy and Carbohydrate Counting Disclosures I do not have any relevant financial relationships with any commercial interests. Henry K. Driscoll, MD, FACP Huntington
More informationDiabetes Update Lanita S. Shaverd, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor, UAMS College of Pharmacy
Objectives Review oral medications used for the treatment of diabetes Explain how to effectively combine oral diabetes medications for optimal results Discuss insulins and non-insulin injectable diabetes
More informationPrimary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD
Primary prevention of chronic kidney disease: managing diabetes mellitus to reduce the risk of progression to CKD Date written: July 2012 Author: Kate Wiggins, Graeme Turner, David Johnson GUIDELINES We
More informationType 2 Diabetes Prevention and Therapy. Veronica Piziak MD, PhD Scott and White
Type 2 Diabetes Prevention and Therapy Veronica Piziak MD, PhD Scott and White Disclosures: Research support: J&J Objectives: Epidemiology of diabetes Diagnosis of diabetes Treatment goals Every Day in
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationAntidiabetic Drugs. Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Antidiabetic Drugs Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Diabetes Mellitus Two types Type 1 Type 2 Type 1 Diabetes Mellitus Lack of insulin production
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More informationMaking Clinical Sense of Diabetes Medications. Types of Diabetes. Pathophysiology. Beta Cell Function & Glucagon
Making Clinical Sense of Diabetes Medications Kathy Reily, RD, CDE Prince William Hospital Diabetes Program Coordinator Virginia Dietetic Association April 4, 2011 Types of Diabetes Type 1 DM = Beta Cell
More informationDiabetes Mellitus Type 2
Diabetes Mellitus Type 2 What is it? Diabetes is a common health problem in the U.S. and the world. In diabetes, the body does not use the food it digests well. It is hard for the body to use carbohydrates
More informationInsulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences
Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of
More informationThe Canadian Diabetes Association s 2013 Clinical Practice Guidelines and the Pharmacist Rob Roscoe, B.Sc.Pharm., ACPR, CDE, CPT
Welcome! Thank you for joining the webinar: The Canadian Diabetes Association s 2013 Clinical Practice Guidelines and the Pharmacist Rob Roscoe, B.Sc.Pharm., ACPR, CDE, CPT The webinar will begin shortly.
More informationGuidelines for Type 2 Diabetes Diagnosis
Guidelines for Type 2 Diabetes Diagnosis Fasting Plasma Glucose (in asymptomatic individuals, repeat measurement to confirm the test) Normal FPG < 100 2-hr OGTT < 140 HbA1C < 5.5% Impaired Fasting Glucose
More informationBACKGROUND INTRODUCTORY MEMORANDUM
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Center for Drug Evaluation and Research BACKGROUND INTRODUCTORY MEMORANDUM From: Hylton V. Joffe, M.D., M.M.Sc.
More informationNewer Anticoagulants and Newer Diabetic Drug Classes. Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013
Newer Anticoagulants and Newer Diabetic Drug Classes Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services August 21, 2013 Apixaban Newer Anticoagulants Dabigatran etexilate Rivaroxaban
More informationThere seem to be inconsistencies regarding diabetic management in
Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional
More information